Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and HAIC in unresectable colorectal cancer liver metastases
NCT05406206Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Colorectal cancer with liver metastases (CRLM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT05406206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406206.